SF1126, a Pan-PI3K inhibitor has potent pre-clinical activity in aggressive B-cell non-Hodgkin lymphomas by inducing cell cycle arrest and apoptosis

Wenqing Qi, Amy Stejskal, Carla Morales, Laurence S. Cooke, Joseph R. Garlich, Donald L Durden, Daruka Mahadevan

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The PI3K pathway is activated in a variety of human tumors including B-cell Non Hodgkin Lymphoma (B-NHL). Targeting this pathway has been validated in solid tumors, leukemia and lymphomas. SF1126, a novel pan-PI3K inhibitor designed by conjugating RGD peptide to LY294002 facilitates clinical testing of this prodrug, suppresses growth and survival of multiple solid tumors in vitro and in vivo. In this study, we demonstrated SF1126 had potent activity in a panel of aggressive B-NHL cell lines. Cells treated with SF1126 exhibited decreased phosphorylation of Akt and GSK-3β confirming the mechanism of action of a PI3K inhibitor. Also, treatment of B-NHL cell lines with SF1126 induced apoptosis in a dose-dependent manner and inhibited cell proliferation with an IC 50 < 4 μM. However, the selective p110δ inhibitor, CAL-101 was less potent in inducing apoptosis and inhibiting cell proliferation compared to SF1126. Moreover, SF1126 induced G1 cell cycle arrest significantly at low concentrations which contributed to suppression of cell proliferation and corroborated to a decrease in cyclin D1. Finally, rituximab enhanced apoptosis induced by SF1126 and CAL-101. Taken together, our findings provide for the first time that SF1126 inhibits the constitutively activated PI3K/Akt pathway in aggressive B-cell NHL cell lines with associated inhibition of cell cycle progression, cell proliferation and promotion of apoptosis. These findings suggest that SF1126 is a novel therapeutic strategy in aggressive B-cell NHL and warrants early phase clinical trial evaluation ± rituximab.

Original languageEnglish (US)
Pages (from-to)207-213
Number of pages7
JournalJournal of Cancer Science and Therapy
Volume4
Issue number7
DOIs
StatePublished - Sep 17 2012

Fingerprint

B-Cell Lymphoma
Cell Cycle Checkpoints
Phosphatidylinositol 3-Kinases
Non-Hodgkin's Lymphoma
Apoptosis
Cell Proliferation
Cell Line
B-Lymphocytes
G1 Phase Cell Cycle Checkpoints
Glycogen Synthase Kinase 3
SF 1126
Neoplasms
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one
Cyclin D1
Prodrugs
Lymphoma
Cell Cycle
Leukemia
Phosphorylation
Clinical Trials

Keywords

  • Apoptosis
  • B-cell non-Hodgkin lymphoma
  • CAL-101
  • Cell cycle
  • PI3K
  • SF1126

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

SF1126, a Pan-PI3K inhibitor has potent pre-clinical activity in aggressive B-cell non-Hodgkin lymphomas by inducing cell cycle arrest and apoptosis. / Qi, Wenqing; Stejskal, Amy; Morales, Carla; Cooke, Laurence S.; Garlich, Joseph R.; Durden, Donald L; Mahadevan, Daruka.

In: Journal of Cancer Science and Therapy, Vol. 4, No. 7, 17.09.2012, p. 207-213.

Research output: Contribution to journalArticle

Qi, Wenqing ; Stejskal, Amy ; Morales, Carla ; Cooke, Laurence S. ; Garlich, Joseph R. ; Durden, Donald L ; Mahadevan, Daruka. / SF1126, a Pan-PI3K inhibitor has potent pre-clinical activity in aggressive B-cell non-Hodgkin lymphomas by inducing cell cycle arrest and apoptosis. In: Journal of Cancer Science and Therapy. 2012 ; Vol. 4, No. 7. pp. 207-213.
@article{262c36aad8eb4d98a028f8880f08ae21,
title = "SF1126, a Pan-PI3K inhibitor has potent pre-clinical activity in aggressive B-cell non-Hodgkin lymphomas by inducing cell cycle arrest and apoptosis",
abstract = "The PI3K pathway is activated in a variety of human tumors including B-cell Non Hodgkin Lymphoma (B-NHL). Targeting this pathway has been validated in solid tumors, leukemia and lymphomas. SF1126, a novel pan-PI3K inhibitor designed by conjugating RGD peptide to LY294002 facilitates clinical testing of this prodrug, suppresses growth and survival of multiple solid tumors in vitro and in vivo. In this study, we demonstrated SF1126 had potent activity in a panel of aggressive B-NHL cell lines. Cells treated with SF1126 exhibited decreased phosphorylation of Akt and GSK-3β confirming the mechanism of action of a PI3K inhibitor. Also, treatment of B-NHL cell lines with SF1126 induced apoptosis in a dose-dependent manner and inhibited cell proliferation with an IC 50 < 4 μM. However, the selective p110δ inhibitor, CAL-101 was less potent in inducing apoptosis and inhibiting cell proliferation compared to SF1126. Moreover, SF1126 induced G1 cell cycle arrest significantly at low concentrations which contributed to suppression of cell proliferation and corroborated to a decrease in cyclin D1. Finally, rituximab enhanced apoptosis induced by SF1126 and CAL-101. Taken together, our findings provide for the first time that SF1126 inhibits the constitutively activated PI3K/Akt pathway in aggressive B-cell NHL cell lines with associated inhibition of cell cycle progression, cell proliferation and promotion of apoptosis. These findings suggest that SF1126 is a novel therapeutic strategy in aggressive B-cell NHL and warrants early phase clinical trial evaluation ± rituximab.",
keywords = "Apoptosis, B-cell non-Hodgkin lymphoma, CAL-101, Cell cycle, PI3K, SF1126",
author = "Wenqing Qi and Amy Stejskal and Carla Morales and Cooke, {Laurence S.} and Garlich, {Joseph R.} and Durden, {Donald L} and Daruka Mahadevan",
year = "2012",
month = "9",
day = "17",
doi = "10.4172/1948-5956.1000143",
language = "English (US)",
volume = "4",
pages = "207--213",
journal = "Journal of Cancer Science and Therapy",
issn = "1948-5956",
publisher = "OMICS Publishing Group",
number = "7",

}

TY - JOUR

T1 - SF1126, a Pan-PI3K inhibitor has potent pre-clinical activity in aggressive B-cell non-Hodgkin lymphomas by inducing cell cycle arrest and apoptosis

AU - Qi, Wenqing

AU - Stejskal, Amy

AU - Morales, Carla

AU - Cooke, Laurence S.

AU - Garlich, Joseph R.

AU - Durden, Donald L

AU - Mahadevan, Daruka

PY - 2012/9/17

Y1 - 2012/9/17

N2 - The PI3K pathway is activated in a variety of human tumors including B-cell Non Hodgkin Lymphoma (B-NHL). Targeting this pathway has been validated in solid tumors, leukemia and lymphomas. SF1126, a novel pan-PI3K inhibitor designed by conjugating RGD peptide to LY294002 facilitates clinical testing of this prodrug, suppresses growth and survival of multiple solid tumors in vitro and in vivo. In this study, we demonstrated SF1126 had potent activity in a panel of aggressive B-NHL cell lines. Cells treated with SF1126 exhibited decreased phosphorylation of Akt and GSK-3β confirming the mechanism of action of a PI3K inhibitor. Also, treatment of B-NHL cell lines with SF1126 induced apoptosis in a dose-dependent manner and inhibited cell proliferation with an IC 50 < 4 μM. However, the selective p110δ inhibitor, CAL-101 was less potent in inducing apoptosis and inhibiting cell proliferation compared to SF1126. Moreover, SF1126 induced G1 cell cycle arrest significantly at low concentrations which contributed to suppression of cell proliferation and corroborated to a decrease in cyclin D1. Finally, rituximab enhanced apoptosis induced by SF1126 and CAL-101. Taken together, our findings provide for the first time that SF1126 inhibits the constitutively activated PI3K/Akt pathway in aggressive B-cell NHL cell lines with associated inhibition of cell cycle progression, cell proliferation and promotion of apoptosis. These findings suggest that SF1126 is a novel therapeutic strategy in aggressive B-cell NHL and warrants early phase clinical trial evaluation ± rituximab.

AB - The PI3K pathway is activated in a variety of human tumors including B-cell Non Hodgkin Lymphoma (B-NHL). Targeting this pathway has been validated in solid tumors, leukemia and lymphomas. SF1126, a novel pan-PI3K inhibitor designed by conjugating RGD peptide to LY294002 facilitates clinical testing of this prodrug, suppresses growth and survival of multiple solid tumors in vitro and in vivo. In this study, we demonstrated SF1126 had potent activity in a panel of aggressive B-NHL cell lines. Cells treated with SF1126 exhibited decreased phosphorylation of Akt and GSK-3β confirming the mechanism of action of a PI3K inhibitor. Also, treatment of B-NHL cell lines with SF1126 induced apoptosis in a dose-dependent manner and inhibited cell proliferation with an IC 50 < 4 μM. However, the selective p110δ inhibitor, CAL-101 was less potent in inducing apoptosis and inhibiting cell proliferation compared to SF1126. Moreover, SF1126 induced G1 cell cycle arrest significantly at low concentrations which contributed to suppression of cell proliferation and corroborated to a decrease in cyclin D1. Finally, rituximab enhanced apoptosis induced by SF1126 and CAL-101. Taken together, our findings provide for the first time that SF1126 inhibits the constitutively activated PI3K/Akt pathway in aggressive B-cell NHL cell lines with associated inhibition of cell cycle progression, cell proliferation and promotion of apoptosis. These findings suggest that SF1126 is a novel therapeutic strategy in aggressive B-cell NHL and warrants early phase clinical trial evaluation ± rituximab.

KW - Apoptosis

KW - B-cell non-Hodgkin lymphoma

KW - CAL-101

KW - Cell cycle

KW - PI3K

KW - SF1126

UR - http://www.scopus.com/inward/record.url?scp=84866128924&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866128924&partnerID=8YFLogxK

U2 - 10.4172/1948-5956.1000143

DO - 10.4172/1948-5956.1000143

M3 - Article

VL - 4

SP - 207

EP - 213

JO - Journal of Cancer Science and Therapy

JF - Journal of Cancer Science and Therapy

SN - 1948-5956

IS - 7

ER -